224 related articles for article (PubMed ID: 23799547)
1. Rosuvastatin prevents pressure overload‑induced myocardial hypertrophy via inactivation of the Akt, ERK1/2 and GATA4 signaling pathways in rats.
Xu X; Zhang L; Liang J
Mol Med Rep; 2013 Aug; 8(2):385-92. PubMed ID: 23799547
[TBL] [Abstract][Full Text] [Related]
2. Rosuvastatin inhibits norepinephrine-induced cardiac hypertrophy via suppression of Gh.
Choi EY; Chang W; Lim S; Song BW; Cha MJ; Kim HJ; Choi E; Jang Y; Chung N; Hwang KC
Eur J Pharmacol; 2010 Feb; 627(1-3):56-62. PubMed ID: 19883640
[TBL] [Abstract][Full Text] [Related]
3. Rosuvastatin attenuates atherosclerosis in rats via activation of scavenger receptor class B type I.
Li Y; Wang Q; Zhou J; Xu Q; Chu X; Sun T; Liu X; Cai S
Eur J Pharmacol; 2014 Jan; 723():23-8. PubMed ID: 24333476
[TBL] [Abstract][Full Text] [Related]
4. Effect of combined treatment with rosuvastatin and protein kinase Cβ2 inhibitor on angiogenesis following myocardial infarction in diabetic rats.
Huang D; Wang FB; Guo M; Li S; Yan ML; Yu T; Wei M; Li JB
Int J Mol Med; 2015 Mar; 35(3):829-38. PubMed ID: 25524396
[TBL] [Abstract][Full Text] [Related]
5. Salvianolic Acid B Alleviates Heart Failure by Inactivating ERK1/2/GATA4 Signaling Pathway after Pressure Overload in Mice.
Yu J; Chen R; Tan Y; Wu J; Qi J; Zhang M; Gu W
PLoS One; 2016; 11(11):e0166560. PubMed ID: 27893819
[TBL] [Abstract][Full Text] [Related]
6. [Rosuvastatin enhances the protective effects of ischemic postconditioning on myocardial ischaemia-reperfusion injury in type 2 diabetic rat].
CAI W; FANG J; CHEN ZY; LIN YL; WU LM; CHEN LL
Zhonghua Xin Xue Guan Bing Za Zhi; 2010 Sep; 38(9):814-8. PubMed ID: 21092651
[TBL] [Abstract][Full Text] [Related]
7. AMPK activation enhances PPARα activity to inhibit cardiac hypertrophy via ERK1/2 MAPK signaling pathway.
Meng R; Pei Z; Zhang A; Zhou Y; Cai X; Chen B; Liu G; Mai W; Wei J; Dong Y
Arch Biochem Biophys; 2011 Jul; 511(1-2):1-7. PubMed ID: 21530483
[TBL] [Abstract][Full Text] [Related]
8. Relation of Cardiotrophin-1 (CT-1) and cardiac transcription factor GATA4 expression in rat's cardiac myocytes hypertrophy and apoptosis.
He-nan Z; Yan W; Miao-na J; Cai-hua Z; Shen L; Yu-jie J
Pathol Res Pract; 2009; 205(9):615-25. PubMed ID: 19327894
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-26a protects against cardiac hypertrophy via inhibiting GATA4 in rat model and cultured cardiomyocytes.
Liu Y; Wang Z; Xiao W
Mol Med Rep; 2016 Sep; 14(3):2860-6. PubMed ID: 27485101
[TBL] [Abstract][Full Text] [Related]
10. Improved cardiac performance by rosuvastatin is associated with attenuations in both myocardial tumor necrosis factor-alpha and p38 MAP kinase activity in rats after myocardial infarction.
Xu Y; Tang T; Ding Y; Yao R; Xie J; Liao M; Xiao H; Chen Y; Yu X; Fu M; Liao Y; Zhao G; Cheng X
Am J Med Sci; 2010 Aug; 340(2):121-7. PubMed ID: 20588182
[TBL] [Abstract][Full Text] [Related]
11. Ameliorative effect of combination of fenofibrate and rosiglitazone in pressure overload-induced cardiac hypertrophy in rats.
Rose M; Balakumar P; Singh M
Pharmacology; 2007; 80(2-3):177-84. PubMed ID: 17570955
[TBL] [Abstract][Full Text] [Related]
12. Multiple signalling pathways underlie the protective effect of levosimendan in cardiac myocytes.
Markou T; Makridou Z; Galatou E; Lazou A
Eur J Pharmacol; 2011 Sep; 667(1-3):298-305. PubMed ID: 21664904
[TBL] [Abstract][Full Text] [Related]
13. Effect of rosuvastatin on insulin sensitivity in an animal model of insulin resistance: evidence for statin-induced hepatic insulin sensitization.
Naples M; Federico LM; Xu E; Nelken J; Adeli K
Atherosclerosis; 2008 May; 198(1):94-103. PubMed ID: 18093597
[TBL] [Abstract][Full Text] [Related]
14. [Sympathetic nerve in rat with pressure overload left ventricular hypertrophy].
Liao Y; Qu XF; Liu L; Dong XM; Yin DC
Zhonghua Yi Xue Za Zhi; 2009 Sep; 89(34):2412-5. PubMed ID: 20137696
[TBL] [Abstract][Full Text] [Related]
15. Regulatory T cells contribute to rosuvastatin-induced cardioprotection against ischemia-reperfusion injury.
Ke D; Fang J; Fan L; Chen Z; Chen L
Coron Artery Dis; 2013 Jun; 24(4):334-41. PubMed ID: 23531479
[TBL] [Abstract][Full Text] [Related]
16. FAK-related nonkinase attenuates hypertrophy induced by angiotensin-II in cultured neonatal rat cardiac myocytes.
Qin J; Liu ZX
Acta Pharmacol Sin; 2006 Sep; 27(9):1159-64. PubMed ID: 16923336
[TBL] [Abstract][Full Text] [Related]
17. Rosuvastatin enhances the therapeutic efficacy of adipose-derived mesenchymal stem cells for myocardial infarction via PI3K/Akt and MEK/ERK pathways.
Zhang Z; Li S; Cui M; Gao X; Sun D; Qin X; Narsinh K; Li C; Jia H; Li C; Han Y; Wang H; Cao F
Basic Res Cardiol; 2013 Mar; 108(2):333. PubMed ID: 23386286
[TBL] [Abstract][Full Text] [Related]
18. Rosuvastatin reduces platelet activation in heart failure: role of NO bioavailability.
Schäfer A; Fraccarollo D; Eigenthaler M; Tas P; Firnschild A; Frantz S; Ertl G; Bauersachs J
Arterioscler Thromb Vasc Biol; 2005 May; 25(5):1071-7. PubMed ID: 15761193
[TBL] [Abstract][Full Text] [Related]
19. Activation or inactivation of cardiac Akt/mTOR signaling diverges physiological from pathological hypertrophy.
Kemi OJ; Ceci M; Wisloff U; Grimaldi S; Gallo P; Smith GL; Condorelli G; Ellingsen O
J Cell Physiol; 2008 Feb; 214(2):316-21. PubMed ID: 17941081
[TBL] [Abstract][Full Text] [Related]
20. Association of RhoGDIalpha with Rac1 GTPase mediates free radical production during myocardial hypertrophy.
Custodis F; Eberl M; Kilter H; Böhm M; Laufs U
Cardiovasc Res; 2006 Jul; 71(2):342-51. PubMed ID: 16698001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
